Kaplan–Meier estimates of tumor related survival measured from the date of first admission stratified by vein invasion status V0 (red) /V1(blue) (left panel) and poorly differentiated medullary cancer (PMC) (blue) vs. other histopathological subtypes (no-PMC) (red) (right panel).

<p>Kaplan–Meier estimates of tumor related survival measured from the date of first admission stratified by vein invasion status V0 (red) /V1(blue) (left panel) and poorly differentiated medullary cancer (PMC) (blue) vs. other histopathological subtypes (no-PMC) (red) (right panel).</p

Immunohistochemical biomarker analysis: All immunohistochemical markers except Ki-67, TP53, and Survivin were analyzed using the semiquantitative scoring system described in the method section.

<p>Immunohistochemical biomarker analysis: All immunohistochemical markers except Ki-67, TP53, and Survivin were analyzed using the semiquantitative scoring system described in the method section.</p

Patient characteristics collected from the patient management software and the regional population-based cancer registry (n = 129).

<p>Patient characteristics collected from the patient management software and the regional population-based cancer registry (n = 129).</p

Immunhistochemical and H&E staining of the TMA of gastric cancer specimens (200x).

<p>Poorly differentiated medullary cancer by H&E staining (A) and CD3 staining (B). TP53 mutated (C) and wildtype (D) tumor sample.</p

Histopathological characteristics of the 80 tumor samples reevaluated from available formalin-fixed paraffin-embedded tissue samples.

<p>PMC: Poorly differentiated medullary cancer.</p